Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2014

01-06-2014 | Review

Genetic unraveling of colorectal cancer

Authors: Sabha Rasool, Vamiq Rasool, Tahira Naqvi, Bashir A. Ganai, Bhahwal Ali Shah

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

Colorectal cancer is a common disease in both men and women (being the third most common cancer in men and the second most common among women) and thus represents an important and serious public health issue, especially in the western world. Although it is a well-established fact that cancers of the large intestine produce symptoms relatively earlier at a stage that can be easily cured by resection, a large number of people lose their lives to this deadly disease each year. Recent times have seen an important change in the incidence of colorectal cancer in different parts of the world. The etiology of colorectal cancer is multifactorial and is likely to involve the actions of genes at multiple levels along the multistage carcinogenesis process. Exhaustive efforts have been made out in the direction of unraveling the role of various environmental factors, gene mutations, and polymorphisms worldwide (as well as in Kashmir—“a valley of gastrointestinal cancers”) that have got a role to play in the development of this disease so that antitumor drugs could be developed against this cancer, first, and, finally, the responsiveness or resistance to these agents could be understood for combating this global issue.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMed
2.
Boyle P, Elena M. Epidemiology of colorectal cancer. British Med Bull. 2002;64:1–25.
3.
World Health Organization (February 2006). Retrieved 24 May 2007.
4.
Paula MC, Harold F. The genetics of CRC. Ann Intern Med. 2002;137:603–12.
5.
Umar A, Greenwald P. Alarming colorectal cancer incidence trends: a case for early detection and prevention. Cancer Epidemiol Biomarkers Prev. 2009;18:1672–3.PubMed
6.
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.PubMed
7.
Fatemi SR, Shivarani S, Malek FN, Vahedi M, Maserat E, Iranpour Y, et al. Colonoscopy screening results in at risk Iranian population. Asian Pac J Cancer Prev. 2010;11:1801–4.PubMed
8.
Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4(4):71–5.PubMedCentralPubMed
9.
Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA, et al. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res. 2010;9:651–60.PubMed
10.
Sameer AS, ul Rehman S, Pandith AA, Syeed N, Shah ZA, Chowdhri NA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15:244–52.PubMedCentralPubMed
11.
Rasool S, Ganai BA, Sameer AS, Masood A. Esophageal cancer: associated factors with special reference to the Kashmir Valley. Tumori. 2012;98:191–203.PubMed
12.
Jenkins TD, Rustgi AK: Genetics of colorectal carcinoma. In: cancer of the lower gastrointestinal tract. Ed. Willet C.G. London 2001;33–44.
13.
Young GP, Hu Y, Le Leu RK, Nyskohus L. Dietary fibre and colorectal cancer: a model for environment–gene interactions. Mol Nutr Food Res. 2005;49(6):571–84.PubMed
14.
Kinzler KW, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill; 2002. p. 583–612.
15.
Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011;6:479–507.
16.
Kupfer SS, Anderson JR, Hooker S, Skol A, Kittles RA, Keku TO, Sandler RS, Ellis NA. Genetic heterogeneity in colorectal cancer associations between African and European Americans. Gastroenterol. 2010;139(5):1677--85.
17.
Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011;135(6):698–703.PubMed
18.
Lee AJX, Endesfelder D, Rowan A, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011;71:1858–70.PubMedCentralPubMed
19.
20.
Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol. 2000;190(4):412–6.PubMed
21.
Lenglauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–7.
22.
Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11(23):8332–40.PubMed
23.
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248.PubMed
24.
World Cancer Research Fund and American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007.
25.
Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263(5153):1625–9.PubMed
26.
Wilmink ABM. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum. 1997;40(4):483–93.PubMed
27.
Jeter JM, Kohlmann W, Gruber SB. Genetics of colorectal cancer. Oncology. 2006;20(3):269–76.PubMed
28.
Ruschoff J, Dietmaier W, Luttges J, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150:1815–25.PubMedCentralPubMed
29.
Cederquist, K. (2005). Genetic and epidemiological studies of hereditary colorectal cancer. Norrlands Universitetssjukhus
30.
Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6.PubMed
31.
Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.PubMed
32.
Vilar E & Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence Nat Rev Clin Oncol. 2010;7(3):153--62.
33.
Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.PubMed
34.
Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23:29–39.PubMed
35.
Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer. 2010;10:227.PubMedCentralPubMed
36.
Toyota M, Ahuja N, Ohe-Toyota M, Herman J, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.PubMedCentralPubMed
37.
Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698.PubMedCentralPubMed
38.
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.PubMed
39.
Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68(20):8541–6.PubMed
40.
Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122(5):1376–87.PubMed
41.
Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73(2):725–35.
42.
Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–38.PubMed
43.
Ahnen DJ. The genetic basis of colorectal cancer risk. Adv Intern Med. 1996;41:531–52.PubMed
44.
Yeatman TJ: Colon cancer. Encyclopedia of Life Sciences; 2001. Macmillan Publishers. p. 1–6.
45.
Pappou EP and Ahuja N. The role of oncogenes in gastrointestinal cancer. Gastrointest. Cancer Res. 2010;2(Suppl 1):S2–S15.
46.
Renkonen ET. Genetic basis of hereditary colorectal cancers. Helsinki University Biomedical Dissertations #75,9–12.
47.
Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene. 1995;10:1581–6.PubMed
48.
Bishop JM. The enemies within: the genesis of retrovirus oncogenes. Cell. 1982;23:5–7.
49.
Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer. 1999;82:640–3.PubMed
50.
Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogenously staining chromosomal regions contain amplified copies of an abundant expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A. 1983;80:1707.PubMedCentralPubMed
51.
Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595–610.PubMed
52.
Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143.PubMed
53.
Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.PubMed
54.
Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303.PubMed
55.
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993;260:85–8.PubMed
56.
Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41(3):185–92.PubMed
57.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMed
58.
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.PubMed
59.
Chan TL, Zhao W, Leung SY, Yuen ST. Cancer Genome Project. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003;63:4878–81.PubMed
60.
Lorentz O, Cadoret A, Duluc I, et al. Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. Oncogene. 1999;18:87–92.PubMed
61.
Guan RJ, Fu Y, Holt PR, Pardee AB. Association of Kras mutations with p16 methylation in human colon cancer. Gastroenterology. 1999;116:1063–71.PubMed
62.
Sameer AS, Chowdri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer. 2009;46:219–25.PubMed
63.
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.PubMed
64.
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308–24.PubMedCentralPubMed
65.
Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, et al. KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Anal Cell Pathol. 2006;28(4):161–6.
66.
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65(14):6063.PubMed
67.
Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol. 2013;34(3):1301–15.
68.
69.
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMed
70.
Carson JD, AllerG V, Lehr R, Sinnamon RH, Kirkpatrick RB, et al. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. J Biochem. 2008;409:519–24.
71.
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.PubMed
72.
Gardner L, Lee L, and Dang C. The c-Myc oncogenic transcription factor. Encyclopedia of Cancer. p. 1–13.
73.
De Pinho R et al. Myc family of cellular oncogenes. J Cell Biochem. 1987;33(4):257–66.
74.
Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004–16.PubMed
75.
Dang CV et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–64.PubMed
76.
77.
Erisman MD et al. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol. 1985;5(8):1969–76.PubMedCentralPubMed
78.
Sikora K et al. c-myc oncogene expression in colorectal cancer. Cancer. 1987;59(7):1289–95.PubMed
79.
Monnat M et al. Prognostic implications of expression of the cellular genes myc, fos, Ha-ras and Ki-ras in colon carcinoma. Int J Cancer. 1987;40(3):293–9.PubMed
80.
Yokota J et al. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science. 1986;231(4735):261–5.PubMed
81.
He TC et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMed
82.
Stewart J et al. Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer. 1986;53(1):1–6.PubMedCentralPubMed
83.
Pavelic ZP et al. High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res. 1992;12(1):171–5.PubMed
84.
Sundaresan V et al. Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis. J Clin Pathol. 1987;40(11):1274–81.PubMedCentralPubMed
85.
Rochlitz CF, Herrmann R, de Kant E. Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology. 1996;53(6):448–54.PubMed
86.
Heerdt BG et al. Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. Oncogene. 1991;6(1):125–9.PubMed
87.
Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.PubMedCentralPubMed
88.
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522–7.PubMedCentralPubMed
89.
Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422–6.PubMed
90.
Arber N et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110(3):669–74.PubMed
91.
Mc Kay JA et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer. 2000;88(1):77–81.
92.
Nosho K et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology. 2008;53(5):588–98.PubMedCentralPubMed
93.
Ogino S et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009;15(13):4431–8.PubMedCentralPubMed
94.
Sameer AS, Parray FQ, Dar MA, Nissar S, Banday MZ, Rasool S, GM Gulzar, Chowdri NA and Siddiqi MA. Cyclin D1 G870A polymorphism and risk of colorectal cancer: a case control study. Mol Med Reports; 2013;7(3):811--5.
95.
Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–25.PubMed
96.
Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine, 2011;12(66):419--32
97.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;22:337–45.
98.
Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–8.PubMed
99.
Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331–46.PubMed
100.
Sirvent A, Benistant C, Roche S. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res. 2012;2(4):357–71.PubMedCentralPubMed
101.
Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513–609.PubMed
102.
Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–58.PubMed
103.
Han NM, Curley SA, Gallick GE. Differential activation of pp 60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res. 1996;2:1397–404.PubMed
104.
Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002;94:344–51.PubMed
105.
Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001;193:483–90.PubMed
106.
Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–9.PubMed
107.
Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;8:573–81.PubMed
108.
Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17:1371–84.PubMedCentralPubMed
109.
Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996;10:1443–54.PubMed
110.
Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol. 2007;27:7551–9.PubMedCentralPubMed
111.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–90.PubMed
112.
Wagenaar RA, Crawford HC, Matrisian LM. Stabilized beta-catenin immortalizes colonic epithelial cells. Cancer Res. 2001;61:2097–104.PubMed
113.
Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130–4.PubMed
114.
Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–47.PubMed
115.
116.
Sameer AS, Shah ZA, Abdullah S, Chowdri NA, Siddiqi MA. Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population. Hum Genomics. 2011;5(5):441–52.PubMedCentral
117.
Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis. 2005;26:2031–45.PubMed
118.
Knudson AG. Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 1985;45:1437–43.PubMed
119.
Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993;90(109):14–21.
120.
Levitt NC, Hickson ID. Caretaker tumour suppressor genes that defend genome integrity. Trends Mol Med. 2002;8:179–86.PubMed
121.
Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000;18:1967–79.PubMed
122.
Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17:45–51.PubMed
123.
Brocardo M, Henderson S. APC shuttling to the membrane, nucleus, and beyond. Trends Cell Biol. 2009;18:587–96.
124.
Lynch HT, De La Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.PubMed
125.
Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13:3784–91.PubMed
126.
Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912–25.PubMed
127.
Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008;7:979–87.PubMed
128.
Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–21.PubMed
129.
Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogenes. 2005;24:2899–908.
130.
Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl. 1997;273:68–73.PubMed
131.
Sameer AS, ul Rehman AA, Pandith AA, Syeed N, Shah ZA, Chowdhri NA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15(4):244–52.PubMedCentralPubMed
132.
Molecular mechanisms involved in colorectal cancer initiation and progression. Oncology Programme 2007 Scientific Report, pp. 118–121.
133.
Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by APC mutation. Cancer Res. 2006;66(20):9837–44.PubMed
134.
Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309.PubMed
135.
Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 1998;58(14):3101–4.PubMed
136.
Samanta D, Datta PK. Alterations in the Smad pathway in human cancers. Front Biosci. 2012;17:1281–93.
137.
Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem Suppl. 1998;30–31:111–22.PubMed
138.
Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138(3):969–80.PubMedCentralPubMed
139.
Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005;11:2606–11.PubMed
140.
Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA. SMAD4—molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer. 2010;10:300.PubMedCentralPubMed
141.
Morán A, Ortega P, de Juan C, Fernández-Marcelo T, Frías C, Sánchez-Pernaute A, et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. World J Gastrointest Oncol. 2010;2(3):151–8.PubMedCentralPubMed
142.
Akkiprik M, Ataizi-Çelikel Ç, Düşünceli F, Sönmez Ö, Güllüoglu BM, Sav A, et al. Clinical significance of p53 K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis. 2007;16:11–7.
143.
Itoh F, Hinoda Y, Ohe M, et al. Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer. 1993;53:260–3.PubMed
144.
Iino H, Fukayama M, Maeda Y, et al. Molecular genetics for clinical management of colorectal carcinoma. Cancer. 1994;73:1324–31.PubMed
145.
Saito M, Yamaguchi A, Goi T, et al. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology. 1999;56:134–41.PubMed
146.
Gotley DC, Reeder JA, Fawcett J, et al. The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene. 1996;13:787–95.PubMed
147.
Tanaka K, Oshimura M, Kikuchi R, Seki M, Hayashi T, Miyaki M. Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18. Nature. 1991;349:340–2.PubMed
148.
Kathleen RC, Jonathan DO, Jonathan WS, Lora H, Eric RF, Antonette CP, et al. The DCC gene: structural analysis and mutations in colorectal carcinoma. Genomics. 1994;19:525–31.
149.
Christelle F, Xin Y, Laure G, Ve'ronique C, Hwain S, Dale EB, et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. PNAS. 2001;98:3416–21.
150.
Adrienne VD, Joseph S, Ellen F, Molly DS. The Drosophila netrin receptor frazzled/DCC functions as an invasive tumor suppressor. BMC Dev Biol. 2011;11:41.
151.
Meimei L, Peiling L, Baoxin L, Changmin L, Rujin Z, Chunjie H. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med. Oncol. 2011;28(1):282–9.
152.
Mustafa A, Çigdem A, Fikret D, Özgür S, Bahadýr MG, Aydin S, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis. 2007;16:11–7.
153.
Shekarabi M, Kennedy TE. The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1. Mol Cell Neurosci. 2002;19:1–17.PubMed
154.
Khan NP, Pandith AA, Hussain MU, Yousuf A, Khan MS, Siddiqi MA, et al. Loss of heterozygosity (LOH) of deleted in colorectal cancer (DCC) gene and predisposition to colorectal cancer: significant association in colorectal cancer patients of Kashmir. J Cancer Res Exp Oncol. 2011;3(8):88–94.
155.
Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk Study: associations with clinicopathological and dietary factors. BMC Cancer. 2011;11:123.PubMedCentralPubMed
156.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMed
157.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.PubMed
158.
Li DM, Sun H. TEP1 encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res. 1997;57:2124–9.PubMed
159.
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–7.PubMed
160.
Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al. Germline mutations in PTEN are present in Bannayan–Zonana syndrome. Nat Genet. 1997;16:333–4.PubMed
161.
Chang JG, Chen YJ, Perng LI, Wang NM, Kao MC, Yang TY, et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer. 1999;35(4):647–51.PubMed
162.
Danielsen SA, Lind GE, Bjornslett M, Meling GI, Rognum TO, Heim S, Lothe RA: Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation status. Hum Mutat. 2008;29(11):E252--62.
163.
Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D, et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res. 2001;7(12):4049–53.PubMed
164.
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004;64(9):3014–21.PubMed
165.
Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene. 2004;23(2):617–28.PubMed
166.
Wang ZJ, Taylor F, Churchman M, Norbury G, Tomlinson I. Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am J Pathol. 1998;153(2):363–6.PubMedCentralPubMed
167.
Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet. 2000;9(2):283–7.PubMed
168.
Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161(2):439–47.PubMedCentralPubMed
169.
170.
Chiou SK, Jones MK, Tarnawski AS. Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 2003;9(4):143–7.
171.
Miller L. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 1999;9:323–8.PubMed
172.
O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000;97:13103–7.PubMedCentralPubMed
173.
Ikeguchi M, Yamaguchi K, Kaibara N. Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol. 2003;24:40–5.PubMed
174.
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res. 1998;58:15–20.
175.
Kawasaki H, Toyoda M, Shinohara H, et al. Expression of surviving correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026–32.PubMed
176.
Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119–25.PubMed
177.
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188–93.PubMed
178.
Ofner D, Riehemann K, Maier H, Reidmann B, Nehoda H, Totsch M, et al. Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer. 1995;72:981–5.PubMedCentralPubMed
179.
Baretton GB, Diebold G, Christoforis G, Vogt M, Muller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer (Phila). 1996;77:255–64.
180.
Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995;1:1103–10.PubMed
181.
Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res. 2001;7:11–8.
182.
Pritchard DM, Potten CS, Korsmeyer SJ, et al. Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene. 1999;18:7287–93.PubMed
183.
Pritchard DM, Print C, O’Reilly L, et al. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene. 2000;19(34):3955–9.PubMed
184.
Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. JBC. 2001;276:32220–9.
185.
Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis. 2000;21:353–9.PubMed
186.
Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–9.PubMed
187.
Bozina N, Bradamante V, Lovric M. Genetic polymorphisms of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity and cancer risk. Arh Hig Rada Toksikol. 2009;60:217–42.PubMed
188.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMed
189.
Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Sebille V, Colman H, et al. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev. 2007;16:1460–7.PubMed
190.
Cotterchio M et al. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:3098–107.PubMedCentralPubMed
191.
Bethke L et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer. 2007;7:123.PubMedCentralPubMed
192.
Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Carcinogenesis. 1993;14:1821–4.PubMed
193.
Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Cancer Res. 1994;54:4103–11.PubMed
194.
Seidegård J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Carcinogenesis. 1990;11:33–6.PubMed
195.
Kodate C, Fukushi A, Narita T, Kudo H, Soma Y, Sato K. Jpn J Cancer Res. 1988;77:226–9.
196.
Zhao ZQ, Guan QK, Yang FY, Zhao P, Zhou B, Chen ZJ. System review and meta-analysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk. Tumour Biol. 2012;33(2):523–35.PubMed
197.
Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993;14:1633.PubMed
198.
Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 1987;47:1466.PubMed
199.
Sameer AS, Nissar S, Qadri Q, Alam S, Baba SM, Siddiqi MA. Role of CYP2E1 genotypes in susceptibility to colorectal cancer in Kashmiri population. Hum Genomics. 2011;5(6):530–7.PubMedCentralPubMed
200.
Sameer AS, Qadri A, Siddiqi MA. GSTP1 I105V polymorphism and susceptibility to colorectal cancer in Kashmiri population. DNA Cell Biol. 2012;31(1):74–9.PubMed
201.
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–6.PubMed
202.
Williams CS, Mann M, DuBios RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–16.PubMed
203.
Egil F. Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431–502.
204.
Subbaramaiah K, Dannenberg AJ. Cyclooxygenase2: a molecular target for cancer prevention and, treatment. Trends Pharmacol Sci. 2003;24:96–102.PubMed
205.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMed
206.
Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.PubMed
207.
Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.PubMed
208.
Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221–7.PubMedCentralPubMed
209.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–9.PubMed
210.
211.
Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002;277:27613–21.PubMed
212.
Chen WS, Liu JH, Wei SJ, Liu JM, Hong CY, Yang WK. Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003;94:253–8.PubMed
213.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84.PubMed
214.
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.PubMed
215.
216.
Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941–51.PubMedCentralPubMed
217.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin–beta-catenin signaling axis. Science. 2005;310:1504–10.PubMed
218.
Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients prognosis. World J Gastroenterol. 2003;9(9):1990–4.PubMed
219.
Müller-Decker K, Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007;46:705–10.PubMed
220.
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
221.
Kim TM, Lee SH, Chung YJ. Clinical applications of next-generation sequencing in colorectal cancers. World J Gastroenterol. 2013;19(40):6784–93.PubMedCentralPubMed
222.
Biancolella M, K Fortini B, Tring S, Plummer SJ, Mendoza-Fandino GA, et al. Identification and characterization of functional risk variants for colorectal cancer mapping to chromosome 11q23.1. Hum Mol Genet. 2013; doi:10.​1093/​hmg/​ddt584.
223.
Javid G, Zargar SA, Rather S, Khan AR, Khan BA, Yattoo GN, et al. Incidence of colorectal cancer in Kashmir Valley, India. Indian J Gastroenterol. 2011;30(1):7–11.PubMed
224.
Fernandez-Rozadilla C, Cazier JB, Tomlinson I, Brea-Fernández A, Lamas MJ, et al. The EPICOLON Consortium, Hemminki K, Bessa X, Andreu M, Jover R, Xicola R, Llor X, Moreno V, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. Hum Genet. 2013; doi:10.​1007/​s00439-013-1390-4
225.
Rasool S, Kadla SA, Khan T, Qazi F, Shah NA, Basu J, et al. Association of a VDR gene polymorphism with risk of colorectal cancer in Kashmir. Asian Pac J Cancer Prev. 2013;14:5833–7.PubMed
226.
Malik MA, Gupta A, Zargar SA, Mittal B. Role of genetic variants of deleted in colorectal carcinoma (DCC) polymorphisms and esophageal and gastric cancers risk in Kashmir Valley and meta-analysis. Tumour Biol. 2013;34:3049–57.PubMed
227.
Nissar S, Lone TA, Banday MZ, Rasool R, Chowdri NA, Parray FQ, et al. Arg399Gln polymorphism of XRCC1 gene and risk of colorectal cancer in Kashmir: a case control study. Oncol Lett. 2013;5:959–63.PubMedCentralPubMed
228.
Wani HA, Beigh MA, Amin S, Bhat AA, Bhat S, Khan H, et al. Methylation profile of promoter region of p16 gene in colorectal cancer patients of Kashmir Valley. J Biol Regul Homeost Agents. 2013;27(2):297–307.PubMed
229.
Khan NP, Pandith AA, Yousuf A, Khan NS, Khan MS, Bhat IA, et al. The XRCC1 Arg399Gln gene polymorphism and risk of colorectal cancer: a study in Kashmir. Asian Pac J Cancer Prev. 2013;14(11):6779–82.PubMed
230.
Wani M, Afroze D, Makhdoomi M, Hamid I, Wani B, Bhat G, et al. Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir Valley. Asian Pac J Cancer Prev. 2012;13(8):4177–81.PubMed
231.
Shah MA, Shaff SM, Lone GN, Jan SM. Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on esophageal cancer risk in the Kashmir Valley. Asian Pac J Cancer Prev. 2012;13(7):3047–52.PubMed
232.
Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis. 2013;51(1):56–60.PubMed
Metadata
Title
Genetic unraveling of colorectal cancer
Authors
Sabha Rasool
Vamiq Rasool
Tahira Naqvi
Bashir A. Ganai
Bhahwal Ali Shah
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1713-7

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue

Research Article

Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460

Research Article

XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis

Research Article

miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma

Research Article

MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours

Research Article

CYP1A1 and CYP2E1 genotypes and risk of esophageal squamous cell carcinoma in a high-incidence region, Kashmir

Research Article

SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits